Project Description:
Title: SPIMD-301: A phase 3 randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the efficacy and safety of daily subcutaneous injections of Elamipretide in subjects with primary mitochondrial disease resulting from pathogenic nuclear DNA mutations (nPMD)
Role: Collaborator (Site PI-Russo)
Funding: Stealth Biotherapeutics
2022-present
Summary: This is a prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Elamipretide in subjects with primary nuclear mitochondrial myopathy.